Jordyn F. Silverstein

Hematology Oncology | Hematology | Oncology

900 Weyburn Place
Suite 14 171
Los Angeles, CA 90095

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Journal: Gynecologic oncology reports

Published: July 03, 2026

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery.

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery.

Journal: JAMA network open

Published: May 21, 2026

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers.

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 31, 2026

Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study.

Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: March 24, 2026

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Journal: Gynecologic oncology

Published: February 23, 2026

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.

Journal: JAMA oncology

Published: January 02, 2026

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer.

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer.

Journal: Current opinion in obstetrics & gynecology

Published: December 29, 2025

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.

Journal: JAMA ophthalmology

Published: December 04, 2025

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

Journal: EBioMedicine

Published: August 16, 2025

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Journal: Future oncology (London, England)

Published: June 12, 2025

Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.

Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 01, 2025

irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

Journal: medRxiv : the preprint server for health sciences

Published: March 17, 2025

Showing 1-12 of 26

Last Updated: 09/26/2026